Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high172.50 13/01/17
52 week low100.00 05/09/17
52 week change -57.00 (-34.03%)
4 week volume389,369 18/11/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
27/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona Pharma plc : Block listing Interim Review

Verona Pharma plc: Block listing Interim Review LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on its block listing, pursuant to ...

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, bought 10,000 shares in the company on the 29th November 2017 at a price of 106.85p. The...

Verona Pharma plc : PDMR Dealing

Verona Pharma plc: PDMR Dealing LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive...

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and set its price target at 327p.

Verona Pharma losses deepen

Verona Pharma said its third-quarter losses more than tripled after research and development costs rose. The company boo...

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or the "Compan...

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment Top-line data from the study now expected in mid-2018 LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutic...

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respirator...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Latest discussion posts More

  • Re: 3% Shareholders 091117 - rhodi

    Cheers Rhodi mol
    21-Nov-2017
    mol42
  • Our Chairman

    fwiw article and apparently interview august 2017 Leaders of disruptive innovation ? what the leaders of the world?s most innovative companies actually do Dr David ...
    18-Nov-2017
    mol42
  • Re: 3% Shareholders 091117 - rhodi

    Rhodi I note your comments re vs however no change in directors and mgt holding % at .5 since May 17 as per recent website update 9 nov and rns update 7 nov. And as we know ...
    18-Nov-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account